Catalpol Alleviates Depression by Inhibiting NLRP3 Inflammasome via TLR4/MAPK/NF-Κb Pathway
Abstract
Background: We aimed to explore catalpol and NF-k. The role of antidepressant and anti-inflammatory effects of b inhibitor in depression induced by chronic unpredictable mild stress (CUMS).
Methods: Under the guidance of Qiqihar Medical University, from January 2020 to January 2021, the weight, sucrose consumption and rest time of mice during swimming were monitored, the neurobehavioral changes of rats under CUMS were used to determine the experimental model; ELISA detection of iNOS, ROS, caspase-1, IL-1 β And IL-18 expression level; Western blotting detection of TLR4, MAPK and NF-κB expression level; LPS-induced cell model. INOS, NLRP3, caspase-1, IL-1 in RT-qPCR and ELISA detection models β And IL-18 expression level;the TLR4, MAPK and NF-κB level were detected by Western blotting.
Results: CUMS can make rats lose weight, reduce sucrose consumption rate and prolong rest time. Catapol can enhance this effect; In the depression model, ROS, NLRP3, NF-κ B and iNOS were up-regulated Catalpol group MAPK, NF-κ Reduced expression of B and TLR4; ROS, caspase-1, IL-1β, IL-18 and iNOS protein increased. Cell model group TLR4, MAPK and NF-κ. The high protein content of B decreased in catalpol group.
Conclusion: Catalpol acts as anti-depressant and anti-inflammatory molecule indepression induced by CUMS. Combination of catalpol with NF-κB inhibitor might play a role in the treatment of depression through regulating the neuroinflammation.
2. Malhi GS, Mann JJ (2018). Depression. Lan-cet, 392: 2299-2312.
3. Chi X, Wang S, Baloch Z, et al (2019). Re-search progress on classical traditional Chinese medicine formula Lily Bulb and Rehmannia Decoction in the treatment of depression. Biomed Pharmacother, 112: 108616.
4. Kaufmann FN, Costa AP, Ghisleni G, et al (2017). NLRP3 inflammasome-driven pathways in depression: Clinical and pre-clinical findings. Brain Behav Immun, 64: 367-383.
5. Su WJ, Zhang Y, Chen Y, et al (2017). NLRP3 gene knockout blocks NF-κB and MAPK signaling pathway in CUMS-induced depression mouse model. Behav Brain Res, 322: 1-8.
6. Zhang X, Liu J, Pang X, Zhao J, Wang S, Wu D (2014). Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-kappaB signal pathway in rat vascular smooth muscle cells. Mol Cell En-docrinol, 395: 61-68.
7. Sheng YN, Luo YH, Liu SB, et al (2020). Zeaxanthin induces a poptosis via ROS-regulated MAPK and AKT signaling pathway in human gastric cancer cells. Onco Targets Ther, 13: 10995-11006.
8. Navarrete M, Cuartero MI, Palenzuela R, et al (2019). Astrocytic p38alpha MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory. Nat Commun, 10: 2968.
9. An Y, Zhang H, Wang C, et al (2019). Acti-vation of ROS/MAPKs/NF-kappaB/NLRP3 and inhibition of ef-ferocytosis in osteoclast-mediated diabet-ic osteoporosis. FASEB J, 33: 12515-12527.
10. Bhattamisra SK, Yap KH, Rao V, Choudhury H (2019). Multiple biological effects of an iridoid glucoside, catalpol and its underlying molecular mechanisms. Biomolecules, 10: 32.
11. Wang JM, Yang LH, Zhang YY, et al (2015). BDNF and COX-2 participate in anti-depressive mechanisms of catalpol in rats undergoing chronic unpredictable mild stress. Physiol Behav, 151: 360-368.
12. Chen J, Yang Y, Lv Z, et al (2020). Study on the inhibitive effect of Catalpol on diabet-ic nephropathy. Life Sci, 257: 118120.
13. Liu A, Zhang B, Zhao W, Tu Y, Wang Q, Li J (2021). Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated sup-pression of NF-kappaB and MAPKs signaling pathways. Bioengineered, 12: 183-195.
14. Cao L, Wang M, Dong Y, Xu B, Chen J, Ding Y, Qiu S, Li L, Karamfilova Zaharieva E, Zhou X, Xu Y (2020). Cir-cular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1α/HK2. Cell Death Dis, 11: 145.
15. Leonard BE (2018). Inflammation and de-pression: a causal or coincidentallink to the pathophysiology? Acta Neuropsychiatr, 30: 1–16.
16. Alcocer-Gomez E, de Miguel M, Casas-Barquero N, et al (2014). NLRP3 inflam-masome is activated in mononuclear blood cells from patients with major de-pressive disorder. Brain Behav Immun, 36: 111-7.
17. Alcocer-Gomez E, Casas-Barquero N, Wil-liams MR, et al (2017). Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major de-pressive disorder. Pharmacol Res, 121: 114-121.
18. Wu X, Wang J, Song L, et al (2021). Catalpol Weakens Depressive-like Behavior in Mice with Streptozotocin-induced Hyper-glycemia via PI3K/AKT/Nrf2/HO-1 Signaling Pathway. Neuroscience, 473:102-118.
19. Rethorst CD, Toups MS, Greer TL, et al (2013). Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry, 18: 1119-24.
20. Bossu P, Piras F, Palladino I, et al (2015). Hippocampal volume and depressive symptoms are linked to serum IL-18 in schizophrenia. Neurol Neuroimmunol Neu-roinflamm, 2: e111.
21. Chao B, Huang S, Pan J, Zhang Y, Wang Y (2020). Saikosaponind downregulates mi-croRNA-155 and upregulates FGF2 to improve depression-like behaviors in rats induced by unpredictable chronic mild stress by negatively regulating NF-kappaB. Brain Res Bull, 157: 69-76.
22. Feng X, Zhao Y, Yang T, et al (2019). Glu-cocorticoid-Driven NLRP3 inflam-masome activation in hippocampal mi-croglia mediates chronic stress-induced depressive-like behaviors. Front Mol Neu-rosci, 12: 210.
23. Kwatra M, Ahmed S, Gawali B, et al (2020). Hesperidin alleviates chronic restraint stress and lipopolysaccharide-induced Hippocampus and Frontal cortex damage in mice: Role of TLR4/NF-kappaB, p38 MAPK/JNK, Nrf2/ARE signaling. Neu-rochem Int, 140: 104835.
24. Afonina IS, Zhong Z, Karin M, Beyaert R (2017). Limiting inflammation-the nega-tive regulation of NF-kappaB and the NLRP3 inflammasome. Nat Immunol, 18: 861-869.
25. Wang W, Mao S, Yu H, et al (2019). Pinellia pedatisecta lectin exerts a proinflammato-ry activity correlated with ROS-MAPKs/NF-κB pathways and the NLRP3 inflammasome in RAW264.7 cells accompanied by cell pyroptosis. Int Immunopharmacol, 66: 1-12.
26. Ye Y, Jin T, Zhang X, et al (2019). Meisoin-digo Protects against Focal Cerebral Is-chemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polari-zation via TLR4/NF-kappaB Signaling Pathway. Front Cell Neurosci, 13: 553.
27. Tang B, Liu D, Chen L, et al (2020). NLRP3 inflammasome inhibitor MCC950 attenu-ates primary dysmenorrhea in mice via the NF-kappaB/COX-2/PG pathway. J Inflamm (Lond), 17: 22.
| Files | ||
| Issue | Vol 52 No 4 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i4.12440 | |
| Keywords | ||
| Depression Inflammasome Therapy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
